Ringkasan AI
We reviewed 161 live results for immune globulin and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Immune Globulin.
We reviewed 161 live results for immune globulin and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Immune Globulin.
Sumber: Takeda Healthcare Philippines, Inc.
Deskripsi
Cuvitru is a 200 mg/mL (20%) liquid protein solution indicated as replacement therapy for adults and pediatric patients (2 years and older) with primary humoral immunodeficiency (PI). This subcutaneous immunoglobulin (SCIG) treatment is designed for ready-to-use infusion with a maximum infusion rate of 60 mL/hr per site, allowing for flexible administration in clinical or home settings.
Paling cocok untuk
primary humoral immunodeficiency patients, pediatric patients 2 years and older, subcutaneous replacement therapy and home infusion management
Penilaian
Sumber: Xembify
Deskripsi
XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration.
Paling cocok untuk
primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration
Penilaian
Sumber: CSL Behring
Deskripsi
Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials.
Paling cocok untuk
primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment
Penilaian
| Bandingkan | Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] | XEMBIFY® (immune globulin subcutaneous, human–klhw) 20% | Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) |
|---|---|---|---|
| Sumber | Takeda Healthcare Philippines, Inc. | Xembify | CSL Behring |
| Deskripsi | Cuvitru is a 200 mg/mL (20%) liquid protein solution indicated as replacement therapy for adults and pediatric patients (2 years and older) with primary humoral immunodeficiency (PI). This subcutaneous immunoglobulin (SCIG) treatment is designed for ready-to-use infusion with a maximum infusion rate of 60 mL/hr per site, allowing for flexible administration in clinical or home settings. | XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration. | Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials. |
| Paling cocok untuk | primary humoral immunodeficiency patients, pediatric patients 2 years and older, subcutaneous replacement therapy and home infusion management | primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration | primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment |
| Tag | |||
| Aksi | Lihat detail | Lihat detail | Lihat detail |
| Penilaian |
Jika Anda ingin memulai dari opsi yang paling seimbang, saya merekomendasikan:
"Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] from Takeda Healthcare Philippines, Inc.."
Saya memilih ini karena As the official local representative of the manufacturer, Takeda ensures that Cuvitru is FDA-approved and meets all regulatory standards for treating primary immunodeficiency in the Philippines.